Additional Ring Containing Patents (Class 544/211)
-
Patent number: 11078412Abstract: The present invention relates to a method of analyzing a polyamine having a plurality of amino groups in the same molecule or a monoamine having an amino group and a phenolic hydroxyl group in the same molecule on the basis of the measurement result of the intensity of excimer fluorescence emitted as a result of the derivatization of the polyamine or the monoamine with a fluorescence derivatization reagent having a pyrene group. The method is characterized in that the fluorescence derivatization reagent comprises 2-chloro-4-methoxy-6-(4-(pyren-1-yl) butoxy)-1, 3, 5-triazine represented by the formula (2).Type: GrantFiled: March 4, 2015Date of Patent: August 3, 2021Assignees: Shimadzu Corporation, Shizuoka Prefecture Public University CorporationInventors: Makoto Ogaito, Azusa Uchida, Kenichiro Todoroki, Tatsuki Nakano, Toshimasa Toyo'Oka
-
Patent number: 10065941Abstract: The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic activity. A compound of Formula (I): wherein Ra and Rb, and Rd and Re are taken together to form oxo or the like; R4a and R4b are hydrogen or the like; n is 1 or the like; R2 is aryl or the like; s and s? is 0 or the like; R9 and R9? are halogen or the like; R20a and R20b are hydrogen, alkyl or the like; u is 1 to 4; R13 is hydrogen or the like, or its pharmaceutically acceptable salt.Type: GrantFiled: June 29, 2017Date of Patent: September 4, 2018Assignee: SHIONOGI & CO., LTD.Inventor: Hiroyuki Kai
-
Patent number: 9845297Abstract: The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and reducing the risk of microbial infections in humans and animals.Type: GrantFiled: October 16, 2015Date of Patent: December 19, 2017Assignee: Melinta Therapeutics, Inc.Inventors: Erin M. Duffy, Ashoke Bhattacharjee, Hardwin O'Dowd, Marco DeVivo, Yanming Du, Sandra Sinishtaj, Yuanqing Tang, Brian T. Wimberly
-
Patent number: 9688668Abstract: The invention relates to inhibitors of Sphingosine Kinase enzymatic activity, and methods of treating diseases and disorders by administering inhibitors of Sphingosine Kinase enzymatic activity.Type: GrantFiled: February 8, 2013Date of Patent: June 27, 2017Assignee: University of Virginia Patent FoundationInventors: Webster L. Santos, Kevin R. Lynch, Timothy L. Macdonald, Andrew Kennedy, Yugesh Kharel, Mithun Rajendra Raje, Joseph Houck
-
Patent number: 9115121Abstract: The present invention relates to compounds corresponding to formula (I) in which: —R1 represents a substituted phenyl; —R2 represents: —a substituted phenyl; —a heteroaromatic group, the said group being unsubstituted or substituted one or more times; —R3 represents a group Alk; —R4 represents a hydrogen atom or a (C1-C4)alkyl; —R5 represents a hydrogen atom, a (C3-C6)cycloalkyl or a (C1-C4)alkyl-O-Alk; —or alternatively R4 and R5, together with the nitrogen atom to which they are attached, constitute a heterocyclic radical chosen from: azetidin-1-yl, pyrrolidin-1-yl, piperid-1-yl, morpholin-4-yl; —R6 represents a group —COOAlk, a group —CONH2 or a group —NHSO2Alk; —Alk represents a (C1-C4)alkyl, which is unsubstituted or substituted one or more times with a halogen atom; in the form of the base or of an acid-addition salt. Preparation process and diagnostic and therapeutic use.Type: GrantFiled: December 11, 2012Date of Patent: August 25, 2015Assignee: SanofiInventors: Joelle Arnaud, Martine Artiaga, Francis Barth, Laurent Hortala, Serge Martinez, Pascale Roux
-
Patent number: 9085559Abstract: A novel heterocyclic compound belonging to ‘triazine-aryl-bis-indoles’, useful for the treatment of asthma. The pathway by which this compound inhibits asthma is also demonstrated. The present invention also provides a process for the preparation of above compounds and their derivatives are presented.Type: GrantFiled: December 31, 2010Date of Patent: July 21, 2015Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Vasanta Madhava Sharma Gangavaram, Jhillu Singh Yadav, Radha Krishna Palakodety, Arun Bandyopadhyay, Siddhartha Roy, Santu Bandyopadhyay, Rakesh Kamal Johri, Subhash Chander Sharma, Balaram Ghosh, Mabalirajan Ulaganathan, Sakshi Balwani, Bholanath Paul, Ashok Kumar Saxena
-
Patent number: 9018209Abstract: The present invention relates to compounds according to the formula I: Where Ra is H or an optionally OH-substituted C1-C3 alkyl; R1 is OR1, an optionally substituted C4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R1 is an optionally substituted C1-C14 hydrocarbyl group or an optionally substituted heterocyclic group; R2, R3 and R4 are each independently H, an optionally substituted C1-C4 alkyl group (preferably CH3, CH2CH3 or CF3), halogen (preferably F, Cl, Br), OR, CN, NO2, a C1-C6 thioether, a C1-C6 thioester group, an optionally substituted CO2R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R4 is H); R is H or an optionally substituted C1-C6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.Type: GrantFiled: September 25, 2006Date of Patent: April 28, 2015Assignee: Yale UniversityInventors: William L. Jorgensen, Juliana Ruiz-Caro, Andrew D. Hamilton
-
Patent number: 9012582Abstract: A resin with a favorable index of refraction and transparency even without using heavy atoms or inorganic oxide fine particles by means of a polymerizable monomer having a 1,3,5-triazine ring represented by formula 1. (In formula 1: A is a group represented by formula 2, (in formula 2: R1 represents a hydrogen atom or a methyl group, T represents an alkylene having 1-10 carbon atoms, and R2 represents O or NH), and B1 and B2 are each independently groups represented by formula 3, formula 4, or formula 5 (in formulas 3-5: R3, R4, and R5 represent an alkyl group having 1-10 carbon atoms, an aryl group, or an aryloxy group, n1 and n3 are integers from 0-5, and n2 is an integer from 0-7, however when there are at least two of each of R3, R4, and R5, these may be the same or different from each other).Type: GrantFiled: August 6, 2010Date of Patent: April 21, 2015Assignee: Nissan Chemical Industries, Ltd.Inventors: Kenichi Osawa, Takuro Oda
-
Patent number: 8952150Abstract: Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.Type: GrantFiled: September 20, 2010Date of Patent: February 10, 2015Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Victor L. Schuster, Yuling Chi, Andrew S. Wasmuth, Richard S. Pottorf, Gary L. Olson
-
Patent number: 8952001Abstract: The invention relates to amino-heteroaryl derivatives having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.Type: GrantFiled: December 20, 2010Date of Patent: February 10, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Simon James Anthony Grove, Angus John Morrison, Craig Jamieson, Ronald Palin, John Kinnaird Ferguson Maclean
-
Publication number: 20150011751Abstract: To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I): wherein R1 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a substituted or unsubstituted heterocyclic fused ring, or a substituted or unsubstituted alkynyl group, R2 represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, R3 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heterocyclic fused ring, R4 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, or a halogen atom, and R5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, or R1 and R5 may be combined to form a saturated or unsaturateType: ApplicationFiled: March 7, 2013Publication date: January 8, 2015Inventors: Wataru Kawahata, Tokiko Asami, Masaaki Sawa, Yuko Asamitsu, Takayuki Irie, Takahiro Miyake, Takao Kiyoi
-
Patent number: 8916557Abstract: The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: April 18, 2012Date of Patent: December 23, 2014Assignee: Bayer Intellectual Property GmbHInventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Gerd Rühter, Carsten Schultz-Fademrecht, Dirk Kosemund, Philip Lienau
-
Publication number: 20140343061Abstract: The present invention relates to compounds corresponding to formula (I) in which: —R1 represents a substituted phenyl; —R2 represents: —a substituted phenyl; —a heteroaromatic group, the said group being unsubstituted or substituted one or more times; —R3 represents a group Alk; —R4 represents a hydrogen atom or a (C1-C4)alkyl; —R5 represents a hydrogen atom, a (C3-C6)cycloalkyl or a (C1-C4)alkyl-O-Alk; —or alternatively R4 and R5, together with the nitrogen atom to which they are attached, constitute a heterocyclic radical chosen from: azetidin-1-yl, pyrrolidin-1-yl, piperid-1-yl, morpholin-4-yl; —R6 represents a group —COOAlk, a group —CONH2 or a group —NHSO2Alk; —Alk represents a (C1-C4)alkyl, which is unsubstituted or substituted one or more times with a halogen atom; in the form of the base or of an acid-addition salt. Preparation process and diagnostic and therapeutic use.Type: ApplicationFiled: December 11, 2012Publication date: November 20, 2014Inventors: Joelle Arnaud, Martine Artiaga, Francis Barth, Laurent Hortala, Serge Martinez, Pascale Roux
-
Publication number: 20140315906Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).Type: ApplicationFiled: May 21, 2012Publication date: October 23, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Dirk Kosemund, Philip Lienau, Gerd Rühter, Carsten Schultz-Fademrecht
-
Patent number: 8859679Abstract: The instant invention relates to storage stable aqueous solutions of stilbene optical brighteners with polyvinyl alcohols which can be directly used by the papermaker in that they may be diluted with water and/or be metered directly into a coating composition, to provide coated papers of a particularly high whiteness.Type: GrantFiled: April 5, 2006Date of Patent: October 14, 2014Assignee: Clariant Finance (BVI) LimitedInventors: Andrew Clive Jackson, Alec Stewart Tindal, Mariela Gauto
-
Publication number: 20140303167Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.Type: ApplicationFiled: August 22, 2012Publication date: October 9, 2014Applicant: LEAD DISCOVERY CENTER GMBHInventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
-
Publication number: 20140288017Abstract: The present invention is directed to novel catechol diether compounds, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV 1 and 2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.Type: ApplicationFiled: October 12, 2012Publication date: September 25, 2014Inventors: William L. Jorgensen, Karen S. Anderson
-
Publication number: 20140225070Abstract: Provided is an organic light-emitting diode including a compound of Formula 1 below: A detailed description of a substituent in Formula 1 above is defined as described in the detailed description.Type: ApplicationFiled: June 21, 2013Publication date: August 14, 2014Applicant: Samsung Display Co., Ltd.Inventors: Jun-Ha Park, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Eun-Young Lee, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jong-Hyuk Lee
-
Publication number: 20140179637Abstract: A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.Type: ApplicationFiled: December 21, 2013Publication date: June 26, 2014Applicants: The Research Foundation for The State University of New York, Northwestern UniversityInventors: Jonathan Leis, Carol Carter
-
Patent number: 8748411Abstract: Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.Type: GrantFiled: May 5, 2006Date of Patent: June 10, 2014Assignee: Centro de Ingenieria Genetica y BiotechnologiaInventors: Rolando Eduardo Rodriguez Fernandez, Roberto Vera Alvarez, Ania De La Nuez Veulens, Yuliet Mazola Reyes, Silvio Ernesto Perea Rodriguez, Boris Ernesto Acevedo Castro, Alexis Musacchio Lasa, Raimundo Ubieta Gómez
-
Publication number: 20140130191Abstract: The invention relates to a compound comprising non-peptide prokineticin receptors antagonists and agents that modulate or inhibit the activity of prokineticin receptors for use in the treatment of immune-mediated diseases of the central nervous system, peripheral nervous system and neuromuscular junctions.Type: ApplicationFiled: June 27, 2012Publication date: May 8, 2014Applicant: FONDAZIONE I.R.C.C.S. ISTITUTO NEUROLOGICO "CARLO BESTA"Inventors: Rosetta Pedotti, Mohamad Abou Hamdan
-
Patent number: 8710174Abstract: A polymer containing a triazine ring-containing repeating unit structure represented by, for example, formula (23) or (24), which alone can achieve high heat resistance, high transparency, high refraction index, high solubility, and low volume shrinkage, without adding a metal oxide.Type: GrantFiled: September 6, 2013Date of Patent: April 29, 2014Assignee: Nissan Chemical Industries, Ltd.Inventors: Naoya Nishimura, Taku Kato, Masaaki Ozawa, Masahiro Hida, Yasuyuki Koide
-
Publication number: 20140045852Abstract: The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: ApplicationFiled: April 18, 2012Publication date: February 13, 2014Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER INTELLECTUAL PROPERTY GMBHInventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bomer, Gerd Rühter, Carsten Schultz-Fademrecht, Dirk Kosemund, Philip Lienau
-
Publication number: 20130239340Abstract: Tanned leather, skin or pelt is produced by non-metal tanning, comprising the step of tanning a bated hide, skin or pelt with a tanning agent (A), the tanning agent (A) being at least one compound of formula (I), wherein Hal signifies chlorine or fluorine, X signifies N or CR Y signifies hydrogen, C1-8-alkyl, C1-4-alkyl-carbonyl, C1-4-alkyl-sulphonyl or a radical of formula (Ia), or (Ib) —(—C2-3 alkylene-O—)q—H??(Ib) R signifies hydrogen or chlorine, q is 1 to 10 and M signifies hydrogen or an alkali metal cation or an ammonium cation, the ammonium cation being a protonated tertiary amine or a quaternary ammonium cation, in a tanning bath, the tanning bath having a pH of from 6 to 10 at the beginning of the tanning step.Type: ApplicationFiled: October 25, 2011Publication date: September 19, 2013Applicant: CLARIANT FINANCE (BVI) LIMITEDInventors: Claus Reineking, Roberta Gamarino, Licia Trimarco, Maurizio Quaglierini, Markus Gisler, Rainer Nusser
-
Publication number: 20130227799Abstract: Tanned leather, skin or pelt is produced by non-metal tanning, comprising the step of tanning a bated hide, skin or pelt with a tanning agent (A), the tanning agent (A) being at least one compound of formula (I), R—NH—Y—SO2—Z??(I), wherein R signifies a radical of formula wherein Hal signifies fluorine or chlorine, X signifies N or CR1, Y signifies an aliphatic, araliphatic or aromatic hydrocarbonic bridge which may optionally be interrupted by a heteroatom or heteroatomic group, Z signifies vinyl, ?-chloroethyl, ?-phosphatoethyl or ?-sulphatoethyl R1 signifies hydrogen or Cl, in a tanning bath, the tanning bath having a pH of from 6 to 10 at the beginning of tanning step.Type: ApplicationFiled: October 25, 2011Publication date: September 5, 2013Applicant: CLARIANT FINANCE (BVI) LIMITEDInventors: Claus Reineking, Roberta Gamarino, Licia Trimarco, Maurizio Quaglierini, Markus Gisler, Rainer Nusser
-
Publication number: 20130205516Abstract: Tanned leather, skin or pelt is produced by non-metal tanning, comprising the step of tanning a bated hide, skin or pelt with a tanning agent (A), the tanning agent (A) being at least one compound of formula (I), wherein X signifies fluorine, chlorine and/or (+NR3)0-1, wherein R is a substituted C1 to C6 alkyl group or an unsubstituted C1 to C6 alkyl group, an unsubstituted C6 to C10 aryl group or a substituted C6 to C10 aryl group or a C5 to C6 heteroaryl group, R1 signifies hydrogen, C1-8-alkyl or an alkyleneoxy radical of formula (Ia), -(—C2-3alkylene-O—)q-H??(Ia) R2 signifies hydrogen or hydroxy, m signifies 1, 2 or 3, q is of from 1 to 10, M signifies hydrogen or an alkali metal cation or an ammonium cation, the ammonium cation being a protonated tertiary amine or a quaternary ammonium cation, in a tanning bath, the tanning bath having a pH of from 6 to 10 at the beginning of tanning step.Type: ApplicationFiled: October 5, 2011Publication date: August 15, 2013Applicant: CLARIANT FINANCE (BVI) LIMITEDInventors: Claus Reineking, Roberta Gamarino, Licia Trimarco, Maurizio Quaglierini, Markus Gisler, Rainer Nusser
-
Publication number: 20130198974Abstract: Tanned leather, skin or pelt is produced by non-metal tanning, comprising the step of tanning a bated hide, skin or pelt with a tanning agent (A), the tanning agent (A) being at least one compound of formula (I), wherein X signifies fluorine or chlorine, and/or (+NR3)0-1, wherein R is a substituted C1 to C6 alkyl group or an unsubstituted C1 to C6 alkyl group, an unsubstituted C6 to C10 aryl group or a substituted C6 to C10 aryl group or a C5 to C6 heteroaryl group.Type: ApplicationFiled: October 5, 2011Publication date: August 8, 2013Applicant: CLARIANT FINANCE (BVI) LIMITEDInventors: Claus Reineking, Roberta Gamarino, Licia Trimarco, Maurizio Quaglierini, Markus Gisler, Rainer Nusser
-
Publication number: 20130190179Abstract: The present invention relates generally to the use of biological or chemical control agents with for controlling insects and nematodes and to methods particularly useful for combating insects or nematodes and/or increasing crop yield in plants that are at least partially resistant to one or more parasitic nematodes or insects.Type: ApplicationFiled: October 13, 2011Publication date: July 25, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Ruediger Hain, Gerhard Johann, Guenter Donn
-
Publication number: 20130172317Abstract: The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): wherein Rh and Rj are taken together to form a bond; Ra and Rb and/or Rd and Re are taken together to form oxo or the like; Rc is hydrogen, substituted or unsubstituted alkyl or the like; Rf is —(CR4aR4b)n—R2; R4a and R4b are hydrogen, substituted or unsubstituted alkyl or the like; R2 is substituted or unsubstituted cycloalkyl or the like; n is an integer of 1 to 4; —Rg is —X—R3; —X— is —O—, —S— or the like; R3 is substituted or unsubstituted cycloalkyl or the like, or its pharmaceutically acceptable salt or a solvate thereof.Type: ApplicationFiled: August 9, 2011Publication date: July 4, 2013Inventors: Hiroyuki Kai, Takayuki Kameyama, Tohru Horiguchi, Kentaro Asahi, Takeshi Endoh, Yasuhiko Fujii, Takuya Shintani, Ken'ichiroh Nakamura, Sae Jikihara, Tsuyoshi Hasegawa, Miho Oohara, Yukio Tada, Toshikatsu Maki, Akira Iida
-
Publication number: 20130137635Abstract: This invention relates to tryptophan hydroxylase inhibitors, compositions comprising them, and methods of their use for the treatment, management and/or prevention of metastatic bone disease.Type: ApplicationFiled: February 9, 2011Publication date: May 30, 2013Applicant: LEXICON PHARMACEUTICALS, INC.Inventor: Arthur Thomas Sands
-
Publication number: 20130131340Abstract: Estrogen-Related Receptor (ERR) modulating compounds and methods for synthesis of said compounds are described.Type: ApplicationFiled: September 20, 2011Publication date: May 23, 2013Inventors: Barry Forman, Donna Yu
-
Publication number: 20130079345Abstract: The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.Type: ApplicationFiled: March 20, 2011Publication date: March 28, 2013Applicants: BAYER INTELLECTUAL PROPERTY GMBH, LEAD DISCOVERY CENTER GMBHInventors: Jan Eickhoff, Peter Nussbaumer, Gerd Ruhter, Carsten Schultz-Fademrecht, Ulrich Lucking, Axel Choidas, Bert Klebl
-
Publication number: 20120316171Abstract: Methods and compositions for the treatment and/or management of cancer are disclosed, which comprise the use of tryptophan hydroxylase inhibitors.Type: ApplicationFiled: November 4, 2010Publication date: December 13, 2012Inventor: Tamas Oravecz
-
Patent number: 8324249Abstract: The invention relates to tetrahydropyridinyl and dihydropyrrolyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X, Y, Z, R1, R2, m, and n are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.Type: GrantFiled: August 3, 2009Date of Patent: December 4, 2012Assignees: Purdue Pharma L.P., Shionogi & Co., Ltd.Inventors: Hidenori Mikamiyama, Chiyou Ni, Bin Shao, Laykea Tafesse
-
Publication number: 20120264728Abstract: The invention relates to amino-heteroaryl derivatives having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.Type: ApplicationFiled: December 20, 2010Publication date: October 18, 2012Inventors: Simon James Anthony Grove, Angus John Morrison, Craig Jamieson, Ronald Palin, John Kinnaird Ferguson Maclean
-
Publication number: 20120214811Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: ApplicationFiled: August 27, 2010Publication date: August 23, 2012Inventors: Ignacio Aliagas, Stefan Gradl, Janet Gunzner, Simon Mathieu, Rebecca Pulk, Joachim Rudolph, Zhaoyang Wen
-
Publication number: 20120190683Abstract: N-Azinyl-N?-aryl ureas and thioureas derivatives are effective at controlling insects.Type: ApplicationFiled: July 22, 2011Publication date: July 26, 2012Applicant: DOW AGROSCIENCES LLCInventors: Noormohamed M. Niyaz, Ricky Hunter, Timothy C. Johnson, Tony K. Trullinger, Annette V. Brown, Kristy Bryan
-
Publication number: 20120190684Abstract: N-Azinyl-N?-aryl ureas and thioureas derivatives are effective at controlling insects.Type: ApplicationFiled: July 22, 2011Publication date: July 26, 2012Applicant: DOW AGROSCIENCES LLCInventors: Noormohamed M. Niyaz, Ricky Hunter, Timothy C. Johnson, Tony K. Trullinger, Annette V. Brown, Kristy Bryan
-
Publication number: 20120142878Abstract: A resin with a favorable index of refraction and transparency even without using heavy atoms or inorganic oxide fine particles by means of a polymerizable monomer having a 1,3,5-triazine ring represented by formula 1. (In formula 1: A is a group represented by formula 2, (in formula 2: R1 represents a hydrogen atom or a methyl group, T represents an alkylene having 1-10 carbon atoms, and R2 represents O or NH), and B1 and B2 are each independently groups represented by formula 3, formula 4, or formula 5 (in formulas 3-5: R3, R4, and R5 represent an alkyl group having 1-10 carbon atoms, an aryl group, or an aryloxy group, n1 and n3 are integers from 0-5, and n2 is an integer from 0-7, however when there are at least two of each of R3, R4, and R5, these may be the same or different from each other).Type: ApplicationFiled: August 6, 2010Publication date: June 7, 2012Inventors: Kenichi Osawa, Takuro Oda
-
Publication number: 20120129862Abstract: The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.Type: ApplicationFiled: May 23, 2011Publication date: May 24, 2012Inventors: Steven J. Coats, Alexey B. Dyatkin, Wei He, Joseph Lisko, Tamara A. Miskowski, Janet L. Ralbovsky, Mark J. Schulz
-
Patent number: 8153788Abstract: Compounds of the formula (I) or salts thereof, in which in which R1 is an optionally substituted amino group or analogous group, and R2 to R7 are each as described herein, are suitable as herbicides and crop growth regulators. The compounds (I) can be prepared by the processes described, via intermediates including novel intermediates for example of the formula (III).Type: GrantFiled: December 14, 2007Date of Patent: April 10, 2012Inventors: Hartmut Ahrens, Hansjörg Dietrich, Thomas Auler, Martin Hills, Heinz Kehne, Dieter Feucht, Stefan Herrmann, Kristian Kather, Stefan Lehr
-
Publication number: 20120058985Abstract: The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed: or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof.Type: ApplicationFiled: April 29, 2011Publication date: March 8, 2012Applicant: DECIPHERA PHARMACEUTICALS, LLCInventors: DANIEL L. FLYNN, MICHAEL D. KAUFMAN
-
Patent number: 8106194Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: GrantFiled: January 6, 2005Date of Patent: January 31, 2012Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo E. J. Kennis
-
Publication number: 20120009151Abstract: Disclosed herein are novel triazines and related compounds, the synthesis thereof, and compositions, including pharmaceutical compositions, comprising the novel triazines and related compounds. Such novel triazines and related compounds function to inhibit or block entry of viruses of the Flaviviridae family, including Hepatitis C virus (HCV), into cells that are susceptible to virus infection. These compounds are useful for the treatment, therapy and/or prophylaxis of viral diseases and infection, including HCV infection.Type: ApplicationFiled: December 19, 2008Publication date: January 12, 2012Applicant: Progenics Pharmaceuticals, Inc.Inventors: Amy Qi Han, Glen A. Coburn, Kathleen P. Provoncha, Yakov Rotshteyn
-
Publication number: 20110319418Abstract: Disclosed are compounds, compositions and methods for treating pain, including inflammatory, visceral, and acute pain. Such compounds are represented by Formula (I) as follows: wherein A1, L1, D, L2, and Q are defined herein.Type: ApplicationFiled: June 27, 2011Publication date: December 29, 2011Inventors: Christopher M. Flores, Paul R. Wade
-
Publication number: 20110319414Abstract: The present invention provides a novel P2X3 and/or P2X2/3 receptor antagonist. A compound represented by the formula (I); wherein Ra, Rb and Rc are, (a) Ra and Rb are taken together ?Z; and Rc is a group represented by R1c; or (b) Rb and Rc are taken together to form a bond; and Ra is a group represented by —Y—R1a; R1a and R1c are each independently hydrogen, substituted or unsubstituted alkyl, etc.; R2 and R3 are each independently substituted or unsubstituted aryl, etc.; R4a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, etc.; X is —N(R5)—, etc.; R5 is hydrogen, substituted or unsubstituted lower alkyl, etc.; —Y— is —O—, etc.; ?Z is ?O, etc.; and n is an integer of 0 to 4.Type: ApplicationFiled: February 10, 2010Publication date: December 29, 2011Inventors: Hiroyuki Kai, Takayuki Kameyama, Tsuyoshi Hasegawa, MIho Oohara, Yukio Tada, Takeshi Endoh
-
Publication number: 20110237436Abstract: A hydrate and an anhydrous crystal form of the sodium salt of 2-iodo-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)carbamoyl]benzenesulfonamide are described. These thermodynamically stable crystal forms have particular advantages in the stability of suspension formulations.Type: ApplicationFiled: March 2, 2011Publication date: September 29, 2011Applicant: BAYER CROPSCIENCE AGInventors: Britta OLENIK, Christian WALDRAFF, Arno RATSCHINSKI, Martin-Holger HINZ, Hans-Joachim RESSEL
-
Patent number: 8013241Abstract: Disclosed is a novel ionic liquid gel electrolyte having high photoelectric conversion efficiency. Also disclosed are a novel dye-sensitized photoelectric conversion device using such an ionic liquid gel electrolyte, and a solar cell composed of such a dye-sensitized photoelectric conversion device. Specifically disclosed is an ionic liquid gel electrolyte obtained by gelling a liquid electrolyte by using an ionic organic oligomer gelling agent represented by the general formulae (1) and (2) below. Also specifically disclosed are a dye-sensitized photoelectric conversion device, wherein the ionic liquid gel electrolyte is arranged between a counter electrode and a dye-absorbed semiconductor substrate which is arranged in contact with a transparent conductive substrate, and a solar cell.Type: GrantFiled: October 16, 2006Date of Patent: September 6, 2011Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Nagatoshi Koumura, Koujirou Hara, Zhong-Sheng Wang, Masaru Yoshida, Nobuyuki Tamaoki
-
Publication number: 20110137031Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: ApplicationFiled: January 6, 2005Publication date: June 9, 2011Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo E.J. Kennis
-
Patent number: 7956185Abstract: Compounds of formula (I) where X1, C1, and D1 are defined herein, are inhibitors of polo-like kinases. The compounds of formula (I) are useful for treatment of diseases of cellular proliferation, such as, for example, cancer.Type: GrantFiled: May 24, 2007Date of Patent: June 7, 2011Assignee: Abbott LaboratoriesInventors: Robert B. Diebold, Stevan W. Djuric, Vincent L. Giranda, Laura A. Hexamer, Nan-Horng Lin, Julie M. Miyashiro, Thomas D. Penning, Magdalena Przytulinska, Thomas J. Sowin, Gerard M. Sullivan, Zhi-Fu Tao, Yunsong Tong, Anil Vasudevan, Le Wang, Keith W. Woods, Zhiren Xia, Henry Q. Zhang